Phaseline

Targets › GPX4

GPX4 (Phospholipid hydroperoxide glutathione peroxidase GPX4): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.

Essential antioxidant peroxidase that directly reduces phospholipid hydroperoxide even if they are incorporated in membranes and lipoproteins. Can also reduce cholesterol hydroperoxide and thymine hydroperoxide (By similarity). (UniProt, P36969)

Open in Phaseline: the race on GPX4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sound PharmaceuticalsEbselen (SPI-1005)
Glutathione peroxidase mimetic
GPX1, GPX2, GPX3, GPX4Phase 3Meniere's Disease; Hearing LossDec 2026

Conditions

Meniere's Disease (1) Hearing Loss (1)

Modalities

small molecule (1)

Companies

Sound Pharmaceuticals (1)

Related targets

GPX1 (1) GPX2 (1) GPX3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.